Your browser is no longer supported. Please, upgrade your browser.
Settings
MBRX Moleculin Biotech, Inc. daily Stock Chart
MBRX [NASD]
Moleculin Biotech, Inc.
Index- P/E- EPS (ttm)-0.32 Insider Own- Shs Outstand15.58M Perf Week-6.84%
Market Cap16.98M Forward P/E- EPS next Y-0.34 Insider Trans- Shs Float8.79M Perf Month6.86%
Income- PEG- EPS next Q-0.11 Inst Own0.60% Short Float4.75% Perf Quarter-27.81%
Sales- P/S- EPS this Y79.80% Inst Trans105.54% Short Ratio0.47 Perf Half Y-80.91%
Book/sh1.40 P/B0.78 EPS next Y-6.30% ROA- Target Price9.26 Perf Year-
Cash/sh0.40 P/C2.74 EPS next 5Y- ROE- 52W Range0.95 - 9.58 Perf YTD-52.19%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-88.62% Beta-
Dividend %- Quick Ratio5.00 Sales past 5Y- Gross Margin- 52W Low14.74% ATR0.13
Employees1 Current Ratio5.00 Sales Q/Q- Oper. Margin- RSI (14)43.71 Volatility15.76% 11.40%
OptionableNo Debt/Eq0.02 EPS Q/Q- Profit Margin- Rel Volume0.85 Prev Close1.13
ShortableYes LT Debt/Eq0.01 EarningsApr 03 AMC Payout- Avg Volume889.29K Price1.09
Recom- SMA20-3.71% SMA50-27.53% SMA200-72.65% Volume759,015 Change-3.54%
Mar-23-17 09:30AM  Orphan Drug Status and Investor Confidence Boost Stock Prices of Moleculin Biotech and Innocoll Holdings Accesswire -16.54%
Mar-22-17 04:05PM  MOLECULIN BIOTECH, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits +24.30%
01:13PM  Moleculin Leukemia Drug Gets Orphan Drug Status at Investopedia
09:35AM  Moleculin Receives Orphan Drug Designation for Annamycin for the Treatment of Acute Myeloid Leukemia Marketwired
Mar-14-17 04:31PM  MOLECULIN BIOTECH, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Mar-10-17 07:30AM  Moleculin to Present at the 29th Annual Roth Capital Conference Marketwired
Feb-23-17 08:04AM  MOLECULIN BIOTECH, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and E -7.08%
Feb-09-17 04:16PM  MOLECULIN BIOTECH, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial State -22.00%
09:09AM  Moleculin Announces Pricing of $5 Million Underwritten Public Offering Marketwired
Jan-19-17 07:00AM  Moleculin Announces Expanded Scientific Advisory Board Marketwired
Dec-13-16 07:30AM  Moleculin Presents Preclinical Data of Novel Inhibitor of Glycolysis at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Marketwired
Nov-21-16 05:02PM  MOLECULIN BIOTECH, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E
07:30AM  Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2016 Marketwired
06:06AM  MOLECULIN BIOTECH, INC. Files SEC form 10-Q/A, Quarterly Report
Nov-18-16 05:07PM  MOLECULIN BIOTECH, INC. Files SEC form 8-K, Non-Reliance on Previous Financials, Audits or Interim Review
04:31PM  Moleculin Biotech gets good verbal Ok from FDA which should cut time to Phase 1/2 trial down
Nov-17-16 07:30AM  Moleculin Announces Positive FDA Guidance Regarding Annamycin IND Marketwired +15.38%
Oct-26-16 08:00AM  Moleculin Announces Advancement of Preclinical Testing for Brain Tumor Drug WP1122 Marketwired +19.46%
Oct-21-16 08:01AM  MOLECULIN BIOTECH, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -18.48%
Oct-20-16 08:00AM  Moleculin Announces Reminder for Conference Call to Discuss Positive Developments Regarding Annamycin Marketwired +60.97%
Oct-17-16 08:00AM  Moleculin Announces Conference Call to Discuss Positive Developments Regarding Annamycin Marketwired -8.92%
Oct-13-16 05:16PM  MOLECULIN BIOTECH, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhib
Oct-11-16 09:41AM  MOLECULIN BIOTECH, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Oct-07-16 08:00AM  Moleculin Announces Accelerated Plan for Clinical Trial Drug Production Marketwired
Sep-28-16 08:32AM  MOLECULIN BIOTECH, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Sep-23-16 08:15AM  MOLECULIN BIOTECH, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:00AM  Moleculin Biotech to Present at OktoberINVESTfest Marketwired
Sep-22-16 08:30AM  SeeThruEquity Initiates Coverage on Moleculin Biotech, Inc. (NASDAQ: MBRX) with a Price Target of $9.26 Accesswire
Sep-12-16 05:02PM  MOLECULIN BIOTECH, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Sep-07-16 08:00AM  Moleculin Announces Participation at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City September 11-13th, 2016 Marketwired
Aug-25-16 02:23PM  A Cascade Of Corporate Exec Hires This Week
06:48AM  MOLECULIN BIOTECH, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statem
Aug-22-16 08:00AM  Moleculin Appoints New Chief Financial Officer Marketwired +7.52%
Aug-18-16 04:59PM  MOLECULIN BIOTECH, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E
Aug-15-16 01:18PM  MOLECULIN BIOTECH, INC. Files SEC form 10-Q, Quarterly Report
08:00AM  Moleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended June 30, 2016 Marketwired
Aug-09-16 04:16PM  MOLECULIN BIOTECH, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:00AM  Moleculin Expands Research Sponsorship at MD Anderson Cancer Center Marketwired
Aug-02-16 09:40AM  MOLECULIN BIOTECH, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Jul-28-16 08:30AM  Moleculin Announces Data on WP1122 Presented at the 28th Annual International Carbohydrate Symposium Marketwired
Jul-27-16 01:18PM  Moleculin Biotech Inc (MBRX): Proceed With Caution at Insider Monkey
Jul-22-16 05:02PM  MOLECULIN BIOTECH, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Jul-19-16 08:30AM  Moleculin Announces Successful Engineering Run for Production of Annamycin Marketwired
Jun-28-16 11:00AM  Moleculin Biotech Selects PCG Advisory Group for Integrated Strategic Communications Marketwired
Jun-17-16 05:18PM  MOLECULIN BIOTECH, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E
Jun-16-16 05:28PM  MOLECULIN BIOTECH, INC. Files SEC form 10-Q, Quarterly Report
08:00AM  Moleculin Biotech, Inc. Reports Financial Results for the First Quarter Ended March 31, 2016 Marketwired
Jun-09-16 11:06AM  5 Stocks Under $10 Set to Soar
Jun-07-16 09:50AM  How this Houston biotech company used Facebook for its IPO at bizjournals.com -6.74%
Jun-02-16 06:13PM  Moleculin Biotech, Inc. Completes NASDAQ Initial Public Offering Marketwired
10:08AM  Moleculin Biotech trading above issue price in market debut at MarketWatch
10:00AM  Moleculin Biotech, Inc. to Present at the 2016 Marcum MicroCap Conference Marketwired
09:56AM  Moleculin Biotech, Inc. Completes Initial Public Offering Marketwired
Moleculin Biotech, Inc., a preclinical-stage pharmaceutical company, focuses on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. The company also develops other drugs, including WP1066 Portfolio, a portfolio of small molecules targeting the modulation of transcription factors involved in the progression of cancer; and WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer and glioblastoma. Moleculin Biotech, Inc. was founded in 2015 and is headquartered in Houston, Texas.